News & Events zu Elutia Inc (ELUT)ELUTElutia Inc

Elutia Completes BioEnvelope Sale, Receives $8M

Elutia (ELUT) has received the full $8M held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific (BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88M transaction. The company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering. The regulatory process remains on track and Elutia continues to expect a favorable FDA clearance decision for NXT-41x in the first half of 2027. NXT-41x is the company's next-generation antibiotic-eluting surgical matrix. It is being developed for use in the $1.5B U.S. plastic and reconstructive surgery market.

Elutia Sells SimpliDerm Business to Cellution for Up to $11M

Elutia announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11M. Elutia will receive $8M in cash at closing, along with up to $3M in technology transfer and commercial milestone payments over the next 18 months. Closing is expected to occur in the second half of 2026, subject to customary closing conditions. The divestiture completes Elutia's previously announced strategic process for SimpliDerm and focuses the company's resources on NXT-41x, its antibiotic-eluting biomatrix for plastic and reconstructive surgery. Under the terms of the agreement, Elutia will receive $8M in cash at closing, along with up to an additional $3M in technology transfer and commercial milestone payments payable over the next 18 months.

Elutia Grants 460,000 Equity Awards to Three New Employees

Elutia announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan. The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options. The Options vest 25% on the first anniversary of the vesting commencement date, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient's continued employment through the applicable vesting date. The Options have an exercise price of $1.09 per share, the closing price of Elutia's common stock on the Nasdaq Capital Market on March 10, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.